Related Experiment Video
Updated: Jul 12, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
EP1 antagonists for the treatment of inflammatory pain
Adrian Hall1, Andy Billinton, Gerard M P Giblin
1Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline plc, New Frontiers Science Park North, Third Avenue, Harlow, Essex, CM19 5AW, UK. adrian.2.hall@gsk.com
Abstract:
This review summarizes the publication and patent literature reporting on prostaglandin E(2) receptor 1 (EP(1)) antagonists from 2006 to the present. Pertinent references from 2005 are also included. New chemical entities disclosed as EP(1) antagonists are highlighted with particular focus on their potential to treat inflammatory pain. In the time period covered by this review there has been a significant increase in the number of publications describing EP(1) antagonists. Several papers detail in vivo efficacy in preclinical models of inflammatory pain and overactive bladder. It is evident that at least one molecule, if not more, has been selected as a development candidate. In addition to acidic antagonists, several research groups have detailed their efforts to identify non-acidic EP(1) antagonists. Progress in this challenging area is evident from the excellent in vitro activity that has been described to date.
Related Concept Videos
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Nociception